Previous Close | 22.46 |
Open | 21.40 |
Bid | 22.10 x 1000 |
Ask | 24.00 x 800 |
Day's Range | 21.09 - 22.10 |
52 Week Range | 15.25 - 29.30 |
Volume | |
Avg. Volume | 15,215 |
Market Cap | 591.734M |
Beta (5Y Monthly) | 1.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.70 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 41.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for CALT
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. FDA has granted an orphan drug exclusivity period of seven years for Nefecon®, expiring in December 2030 based on Calliditas obtaining full approval with a new indication for this drug product in December 2023.
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug exclusivity period of seven years for TARPEYO®, expiring in December 2030 based on when the company obtained full approval with a new indication for this drug product.
Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.